BURLINGTON, ON, Dec. 11, 2012 /CNW/ - EKO INTERNATIONAL CORP. - (EKNL -
Pinksheets) is pleased to announce that NeuroVasc Clinical Inc. (NCI)
has made arrangements to attend the Walmart Canada Professional
Services Conferences of 2013 in Vancouver, BC (April 4-7) and in
Toronto, ON (April 25-28).
The Conference will provide NCI with access to 350 Walmart Pharmacists
across Canada. NCI will present information explaining the benefits
available to patients suffering with Diabetic Peripheral Neuropathy
(DPN) by receiving FREMS treatments.
FREMS will be showcased at the conference and the procedures for
administering the treatment of patients diagnosed with DPN will be
demonstrated to Walmart's Healthcare Providers.
NCI will present its state-of-the-art equipment as part of the solution
to Walmart's search for leading edge professional strategies and tools
to promote sustainable practice changes in the delivery of health care.
Diabetes Educators at Walmart Pharmacies throughout Ontario are
currently able to provide accurate testing for (DPN) and it is the goal
of NCI to have this capability expanded to all Walmart Pharmacies
Pharmacists provide the front line of care and support to most diabetic
patients in Canada. At these two important conferences, NCI will ensure
that the role of accurate testing for peripheral neuropathy is
reinforced and demonstrated. Further, NCI can provide support to those
patients identified as suffering from peripheral neuropathy by
informing their pharmacist and/or diabetic educator of a FREMs facility
within the community to which they can directly refer those patients.
This press release contains forward-looking statements that reflect the
Company's current expectation regarding future events. Actual events
could differ materially and substantially from those projected herein
and depend on a number of factors. Certain statements in this release,
and other written or oral statements made by EKO International ("The
Company") are "forward-looking statements" within the meaning of
Section 27A of the Securities Act of 1933 and Section 21E of the
Securities Exchange Act of 1934. You should not place undue reliance on
forward-looking statements since they involve known and unknown risks,
uncertainties and other factors, which are, in some cases, beyond the
Company's control and which could, and likely will, materially affect
actual results, levels of activity, performance or achievements. The
Company assumes no obligation to publicly update or revise these
forward-looking statements for any reason, or to update the reasons
actual results could differ materially from those anticipated in these
forward-looking statements, even if new information becomes available
in the future. Important factors that could cause actual results to
differ materially from the company's expectations include, but are not
limited to, those factors that are disclosed under the heading "Risk
Factors" and elsewhere in documents filed by the company from time to
time with the United States Securities and Exchange Commission and
other regulatory authorities.
SOURCE: EKO INTERNATIONAL CORP.
For further information:
To contact the company by e-mail, please use firstname.lastname@example.org